Key Highlights

● Stifel upgraded STAAR Surgical to Buy from Hold on September 29, 2026, and raised its target to $31 from $28.

● Stifel expects Revenue growth to inflect in the second half of 2026 on a shift toward EVO+ lens in China.

● The shares traded near $22.46 at one point, and had already been higher in premarket trading.

● The rally stood out because the Russell 2000 finished lower and health care was mixed on the day.

STAAR Surgical Company (NASDAQ:STAA) surged on Tuesday, September 29, 2026, landing among the S&P SmallCap 600's top gainers after Stifel upgraded the stock to Buy from Hold. The shares traded at about $22.46 at one point and had already been higher in premarket trading.

The Upgrade

Stifel analyst Thomas Stephan raised his price target to $31 from $28 alongside the upgrade. His case rests on a turn in growth. He said revenue growth is poised to inflect in the second half of 2026, driven by a favorable product mix shift toward the higher-priced EVO+ implantable collamer lens in China. In plain terms, Stifel expects STAAR to sell more of its premium lens in its most important market, lifting both sales and the average price per unit.

What STAAR Sells

STAAR makes implantable collamer lenses, known as ICLs, which are placed inside the eye to correct nearsightedness and other vision problems. Unlike laser procedures such as LASIK, which reshape the cornea, an ICL sits behind the iris in front of the eye's natural lens and can be removed if needed. The EVO family is its flagship product line.

Why the Call Matters

China has been central to STAAR's story for years, making Demand trends there a major swing factor. Price-target changes and upgrades often move smaller stocks sharply, because fewer analysts cover them and a single change in view can shift sentiment quickly. Tuesday's gain also came when smaller companies lagged, which made the rally stand out.

Health Care Had a Mixed Day

Health care was among the declining sectors at midday. In biotech, Iovance Biotherapeutics soared after raising its revenue guidance, while uniQure plunged after new data from its Huntington's disease gene therapy.

Index Scorecard

Rising long-term Treasury yields were the main weight on the market, with the 30-year at its highest level since 2002 and the 10-year near a two-decade high. The Conference Board's index of consumer confidence slid to 81.9, a 12-year low, from 88.6 the month before. New York Fed President John Williams said there is no need for urgency after the central bank's September meeting, and odds of an October rate hike fell to roughly a coin flip.

The Test Ahead

The key test of Stifel's thesis is whether revenue growth picks up in the second half of 2026. GDP and August PCE Inflation arrive on Wednesday, September 30, Nike reports on Thursday, October 1, and the September jobs report follows on Friday, October 2.